Alle Fotos(1)
Wichtige Dokumente
SHC007
MISSION® Luciferase shRNA Control Vector
shRNA sequence targeting luciferase
Synonym(e):
MISSION® Control Vectors
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empfohlene Produkte
Qualitätsniveau
Produktlinie
MISSION®
Konzentration
500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)
Versandbedingung
dry ice
Lagertemp.
−20°C
Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich
Allgemeine Beschreibung
The MISSION® Luciferase shRNA Control Vector is a 7,091 base pair lentivirus plasmid vector that contains an shRNA sequence targeting luciferase from Photinus pyralis (GenBank Accession No. M15077). The Luciferase shRNA Control Vector is useful as a positive knockdown control in experiments using cell lines expressing firefly luciferase. It can also be used as a negative control vector.
Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids, MISSION® Lentiviral Packaging Mix (Prod. No. SHP001). The Luciferase shRNA Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.
Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids, MISSION® Lentiviral Packaging Mix (Prod. No. SHP001). The Luciferase shRNA Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.
Anwendung
To see more application data, protocols, vector maps visit sigma.com/shrna.
Rechtliche Hinweise
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Empfehlung
Lagerklassenschlüssel
10 - Combustible liquids
WGK
WGK 3
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Kunden haben sich ebenfalls angesehen
Vajiheh Neshati et al.
Applied biochemistry and biotechnology, 186(1), 245-255 (2018-03-27)
Since the adult mammalian heart has limited regenerative capacity, cardiac trauma, disease, and aging cause permanent loss of contractile tissue. This has fueled the development of stem cell-based strategies to provide the damaged heart with new cardiomyocytes. Bone marrow-derived mesenchymal
Deepak Bararia et al.
Nature communications, 7, 10968-10968 (2016-03-24)
CCAAT/enhancer-binding protein alpha (C/EBPα) is an essential transcription factor for myeloid lineage commitment. Here we demonstrate that acetylation of C/EBPα at lysine residues K298 and K302, mediated at least in part by general control non-derepressible 5 (GCN5), impairs C/EBPα DNA-binding
Islands of spatially discordant APD alternans underlie arrhythmogenesis by promoting electrotonic dyssynchrony in models of fibrotic rat ventricular myocardium.
Majumder R
Scientific Reports, 6 (2016)
Victoria J Gennaro et al.
BMC cancer, 19(1), 258-258 (2019-03-25)
The oncoprotein MYC has the dual capacity to drive cell cycle progression or induce apoptosis, depending on the cellular context. BAG1 was previously identified as a transcriptional target of MYC that functions as a critical determinant of this cell fate
Stephen C Mack et al.
Nature, 553(7686), 101-105 (2017-12-21)
Genomic sequencing has driven precision-based oncology therapy; however, the genetic drivers of many malignancies remain unknown or non-targetable, so alternative approaches to the identification of therapeutic leads are necessary. Ependymomas are chemotherapy-resistant brain tumours, which, despite genomic sequencing, lack effective
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.